Gregory Nelson

Gregory Nelson

January 29, 2013 | Inside Counsel

IP: What every bioscience company needs to know about provisional applications

The upcoming changes to the U.S. patent law, and particularly the transition from a first-to-invent to a first-to-file system on March 16, 2013, brings with it some changes that bioscience companies should be aware of and which could adversely impact pending patent rights.

By Gregory Nelson

4 minute read

January 15, 2013 | Inside Counsel

IP: Are bioscience patents worthwhile?

A recent discussion on a major television network business program addressed the purported deficiencies of the U.S. patent system.

By Gregory Nelson

3 minute read

January 01, 2013 | Inside Counsel

IP: Supreme Court will decide if human genes are patentable

On Nov. 30, 2012, the Supreme Court granted a writ of certiorari in the case of The Association for Molecular Pathology, et al v. Myriad Genetics Inc.

By Gregory Nelson

3 minute read

December 18, 2012 | Inside Counsel

IP: 6 issues for bioscience companies to consider in 2013

As 2013 approaches, some major changes to the patent system will soon take effect.

By Gregory Nelson

3 minute read

December 04, 2012 | Inside Counsel

IP: University-industry transactions becoming more prominent

The significance of a relationship between a university and an industry partner has never been more important for both academia and industry.

By Gregory Nelson

4 minute read

November 20, 2012 | Inside Counsel

IP: Learn to craft a strategic intellectual property policy for a bioscience company

A strategic intellectual property policy is a coordinated approach to the identification, creation and enforcement of intellectual property.

By Gregory Nelson

7 minute read